Summary & Overview
CPT 54505: Incisional Biopsy of Testis, Surgical Procedure
CPT code 54505 is designated for the incisional biopsy of the testis, a surgical procedure critical for diagnosing a range of testicular disorders, including malignancies and other abnormalities. This code is widely recognized across major national payers, including Aetna, Blue Cross Blue Shield, Cigna Health, Medicare, and UnitedHealthcare, ensuring broad coverage for patients requiring this diagnostic intervention.
The publication provides a comprehensive overview of CPT 54505, detailing its clinical significance, typical sites of service, and its role in the diagnostic pathway for male genital organ disorders. Readers will gain insights into payer coverage, relevant modifiers, associated provider taxonomies, and common ICD-10 diagnoses linked to this procedure. Additionally, the article highlights related CPT codes for testicular procedures, offering context for coding and billing professionals.
Key benchmarks and policy updates are discussed, equipping stakeholders with the latest information on reimbursement trends and clinical utilization. The summary is intended for healthcare administrators, coding specialists, and clinicians seeking clarity on the procedural and billing aspects of testicular incisional biopsy. The content is structured to support informed decision-making and accurate coding practices in a national context.
CPT Code Overview
CPT 54505 represents an incisional biopsy of the testis, performed as a separate surgical procedure. This code is used when a tissue sample is required for diagnostic purposes, typically to evaluate disorders or abnormalities of the testis. The procedure is classified as a surgical service and is most commonly conducted in an operating room or ambulatory surgical center, such as a hospital outpatient facility. The incisional biopsy allows for a more comprehensive tissue assessment compared to needle biopsy, aiding in the diagnosis and management of various testicular conditions.
Clinical & Coding Specifications
Clinical Context
A typical patient scenario involves a male patient presenting with symptoms or findings suggestive of a testicular disorder, such as a mass, swelling, pain, or abnormal imaging results. The patient may have a suspected malignancy, infection, or other testicular pathology that cannot be diagnosed through non-invasive means. After clinical evaluation and imaging, the provider determines that an incisional biopsy of the testis is necessary to obtain tissue for definitive diagnosis. The procedure is performed in an operating room or ambulatory surgical center, often under anesthesia, by a urology physician, surgical oncologist, or colon & rectal surgeon. The workflow includes preoperative assessment, surgical biopsy, specimen handling for pathology, and postoperative care.
Coding Specifications
-
Modifiers:
- Modifier
26: Used to indicate the professional component of the service, typically when the physician interprets the results but does not provide the technical aspect. - Modifier
TC: Used for the technical component, representing the facility or equipment portion of the service. - Modifier
59: Used to denote a distinct procedural service, indicating that the procedure is separate from other services performed on the same day.
- Modifier
-
Provider Taxonomies:
Code Specialty 208800000XUrology Physician 208C00000XColon & Rectal Surgery 207XS0117XSurgical Oncology Physician
These specialties are typically involved in performing or interpreting the biopsy of the testis.
Related Diagnoses
-
N50.9- Disorder of male genital organs, unspecified- Used when the patient presents with non-specific symptoms or findings related to the male genital organs, warranting further investigation such as biopsy.
-
C62.9- Malignant neoplasm of testis, unspecified- Indicates suspicion or confirmation of testicular cancer, often necessitating biopsy for diagnosis.
-
N45.1- Epididymo-orchitis, unspecified- Represents inflammation of the epididymis and testis, which may require biopsy if the diagnosis is unclear or to rule out malignancy.
-
N44.00- Torsion of testis, unspecified- Testicular torsion may lead to biopsy if there is concern for underlying pathology or to assess tissue viability.
-
N43.3- Hydrocele, unspecified- Hydrocele may be associated with other testicular abnormalities; biopsy may be performed if there is suspicion of underlying disease.
Related CPT Codes
-
54500- Biopsy of testis, needle (separate procedure): Used for needle biopsy, a less invasive alternative to incisional biopsy. May be considered when tissue sampling is needed but open surgery is not indicated. -
54512- Excise lesion testis: Used when a specific lesion is excised from the testis, often following biopsy if a lesion is identified. -
54520- Removal of testis: Refers to orchiectomy, a more extensive procedure performed if malignancy or severe disease is confirmed. -
54522- Orchiectomy, partial: Partial removal of the testis, typically for localized disease. -
54530- Removal of testis: Another code for orchiectomy, may differ in approach or extent from54520. -
54535- Extensive testis surgery: Used for more complex or extensive surgical interventions on the testis. -
54550- Exploration for testis: Used when surgical exploration is performed to assess testicular pathology, often preceding biopsy or excision.
These codes may be used as alternatives or in conjunction with 54505, depending on the clinical scenario and findings during surgery.
National Reimbursement Benchmarks
Nationally, the mean rate for CPT code 54505 under Medicare is $197.18, while the average commercial benchmark (BUCA) is $286.93. Commercial payers such as UnitedHealth Group and Cigna report even higher mean rates, at $373.32 and $358.18 respectively, compared to Blue Cross Blue Shield at $285.84 and Aetna at $188.35.
Rate dispersion, measured by the difference between the 75th and 25th percentiles, varies significantly across payers. Medicare shows the tightest range ($203.00 - $189.00 = $14.00), indicating minimal variation. In contrast, UnitedHealth Group exhibits the widest spread ($454.00 - $234.50 = $219.50), followed by Cigna ($424.00 - $238.00 = $186.00). This suggests greater variability in commercial reimbursement rates compared to Medicare.
The table and chart below present a detailed breakdown of national mean rates and percentile values for each payer.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.